drs < drug < druggable

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by drug

Number of relevant bibliographic references: 84.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000100 (2020)	Chang-Quan Ling	Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2)
000167 (2020)	Leon Caly [Australie] ; Julian D. Druce [Australie] ; Mike G. Catton [Australie] ; David A. Jans [Australie] ; Kylie M. Wagstaff [Australie]	The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
000183 (2020)	Sophie Alexandra Baron [France] ; Christian Devaux [France] ; Philippe Colson [France] ; Didier Raoult [France] ; Jean-Marc Rolain [France]	Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?
000185 (2020)	Rameez Jabeer Khan [Inde] ; Rajat Kumar Jha [Inde] ; Gizachew Muluneh Amera [Inde] ; Monika Jain [Inde] ; Ekampreet Singh [Inde] ; Amita Pathak [Inde] ; Rashmi Prabha Singh [Inde] ; Jayaraman Muthukumaran [Inde] ; Amit Kumar Singh [Inde]	Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase.
000330 (2020)	Tarek Mohamed Abd El-Aziz [États-Unis, Égypte] ; James D. Stockand [États-Unis]	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
000383 (2020)	Bo Ram Beck [Corée du Sud] ; Bonggun Shin [Corée du Sud, États-Unis] ; Yoonjung Choi [Corée du Sud] ; Sungsoo Park [Corée du Sud] ; Keunsoo Kang [Corée du Sud]	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
000415 (2020)	Laure Elens [Belgique] ; Loralie J. Langman [États-Unis] ; Dennis A. Hesselink [Pays-Bas] ; Stein Bergan [Norvège] ; Dirk Jan A R. Moes [Pays-Bas] ; Mariadelfina Molinaro [Italie] ; Raman Venkataramanan [États-Unis] ; Florian Lemaitre [France]	Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.
000450 (2020)	Subramanian Boopathi [Chili] ; Adolfo B. Poma [Pologne] ; Ponmalai Kolandaivel [Inde]	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment.
000457 (2020)	Yadi Zhou [États-Unis] ; Yuan Hou [États-Unis] ; Jiayu Shen [États-Unis] ; Yin Huang [États-Unis] ; William Martin [États-Unis] ; Feixiong Cheng [États-Unis]	Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
000483 (2020)	Tony Y. Zhang [République populaire de Chine] ; Boyu Zhong [République populaire de Chine]	Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19.
000559 (2020)	Bhumi Shah [Inde] ; Palmi Modi [Inde] ; Sneha R. Sagar [Inde]	In silico studies on therapeutic agents for COVID-19: Drug repurposing approach.
000821 (2020)	Sandro G. Viveiros Rosa [Brésil] ; Wilson C. Santos [Brésil]	Clinical trials on drug repositioning for COVID-19 treatment
000953 (2020)	B. Robson	COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles’ heel conserved region to minimize probability of escape mutations and drug resistance
000B74 (2019)	Allison L. Totura ; Sina Bavari	Broad-spectrum coronavirus antiviral drug discovery
000C59 (2018)	Luca Sancineto [Pologne] ; Nunzio Iraci [Italie] ; Oriana Tabarrini [Italie] ; Claudio Santi [Italie]	NCp7: targeting a multitasking protein for next-generation anti-HIV drug development part 1: covalent inhibitors.
000D45 (2017)	Woo-Jin Shin [États-Unis] ; Baik Lin Seong [Corée du Sud]	Type II transmembrane serine proteases as potential target for anti-influenza drug discovery.
000F38 (2016)	Fenghua Wang [République populaire de Chine] ; Cheng Chen [République populaire de Chine] ; Wenjie Tan [République populaire de Chine] ; Kailin Yang [États-Unis] ; Haitao Yang [République populaire de Chine]	Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design
001059 (2016)	Alimuddin Zumla ; Jasper F. W. Chan ; Esam I. Azhar ; David S. C. Hui [Hong Kong] ; Kwok-Yung Yuen	Coronaviruses — drug discovery and therapeutic options
001100 (2016)	Benjamin A. Wilson [États-Unis] ; Nandita R. Garud [États-Unis] ; Alison F. Feder [États-Unis] ; Zoe J. Assaf [États-Unis] ; Pleuni S. Pennings [États-Unis, Pays-Bas]	The population genetics of drug resistance evolution in natural populations of viral, bacterial and eukaryotic pathogens
001127 (2016)	Yoshio Hamada [Japon] ; Yoshiaki Kiso [Japon]	New directions for protease inhibitors directed drug discovery
001269 (2015)	Michael Berry [Afrique du Sud] ; Burtram C. Fielding [Afrique du Sud] ; Junaid Gamieldien [Afrique du Sud]	Potential Broad Spectrum Inhibitors of the Coronavirus 3CLpro: A Virtual Screening and Structure-Based Drug Design Study.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i -k "drug" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i  \
                -Sk "drug" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Title.i
   |clé=    drug
}}

---

This area was generated with Dilib version V0.6.33. Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021